Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Getting exciting. Easy buy down here for me personally.
Yep. Time to back up the truck here. Our time is near.
Load up the truck time down here.
Today's PPS is basically a Black Friday Sale on steroids.
One hell of a Buying opportunity right here in my opinion. Incredible PPS considering what is in motion.
Same to you and thank you for your regular contributions to this board. Best wishes to all.
One hell of a buy opportunity right here IMO.
Yes, BUY & HODL SHIB is my personal strategy.
Couldn’t give a monkey’s chuff what yours is son. Imagine you have nothing.
Agreed. Buying as much as I can and hodling the lot for the future.
Agree now is buy (add) time for me.
Agree 100% and as such am adding big to my SHIB count and holding. Easy decision.
The practice of MM manipulators should absolutely be outlawed. I liken them to the shit on the heel of any investor’s boot.
Well said and I fully concur. I remain bullish on Revive and like all serious investors am placing considerable trust / faith in CEO Michael Frank. My #1 investment in fact. In for a penny, in for a pound and all that.
Thank you for sharing this Reddit post on Revive's Bucillamine.
Another good looking day. Exciting investment GlobeStar is.
Let's all proactively spread the word / awareness about GlobeStar. A BUY & HOLD stock if ever I saw one.
Buying (adding) big down here in the seasonal bargain basement. Easy decision.
LOL. Imagine the $ difference in CAPITAL GAINS if Longs or anyone for that matter were to sell now only to buy back in in a few weeks time. Financially irresponsible and highly risky on a timing level..
Indeed. I am not worried though. We are so close now. Come on, FDA..do the right thing.
Thank you for the cheap shares, crazy people. Talk about 11th hour.
Er...very serious buy / add opportunity down here. Nom nom...
100% agree. Khiron has a golden set-up and I wholeheartedly believe it is the best cannabis investment at this point.
Noted re Zinc for sore throats...many thanks, Mike!
Great add / buy price right here.
MindMed has developed the ability to remove the (often uncomfortable) "trip" from the dosage but maintain the benefits. Massively pioneering.
I have, do and will continue to do so. What you put in your body is your business obviously but do not assume we all follow suit. Truthfully, your overall claim ref India being such a concern / negative in the context of our shared investment is so inflated. Btw I am not Indian and I live in the U.S. Good luck to us all. My sense is we are being positioned for success here. Adding to my already sizable share count regularly and holding.
I agree. Good ole Crypto.com also.
Me too. Big confidence in ATAI.
This company and stock is going to fly given time IMO. As such, I am taking full advantage by buying (adding) often.
Serious Buy time IMO. Good luck whatever direction your junk hangs peeps.
Not worried. Today was a shock announcement-driven crash thanks to SBF and Binance. DOGE shall prevail soon enough IMO.
100% agree reSolana’s future. Examine the utility, people. Easy investment.
Covid is most certainly not over. We need to tactfully and tastefully spread the word about Bucillamine and it’s diverse health benefits. The saddest most cruel outcome would be for it to be passed by (for whatever flawed 2020’s / Big Pharma reason). #ittakesonebigpharmatorulecovidsolutuonsjesush
Bag holding frankly. Leadership are yet to produce any shareholder value. Hope this is not a scam per se.
Exactly. Buying more SHIB regularly for the future.
Down almost -6% based on a mere x15 shares traded so far this morning. This stinks of manipulation. Revolting.
PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome
Post published:November 2, 2022
Post category:Press Release
TORONTO, Nov. 01, 2022 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on developing and commercializing novel uses and delivery forms of ketamine to treat mental health, neurological and pain disorders, is pleased to announce that the Company has entered into an evaluation and exclusive option agreement (the “Agreement”) with Case Western Reserve University (“CWRU”) in the development and commercialization for the intellectual property of ketamine in the treatment Rett Syndrome, a rare genetic neurological disorder. Ketamine has been subject to a Phase 2 clinical trial (NCT03633058) for Rett syndrome and unpublished results will be evaluated to support a defined clinical and regulatory plan for FDA feedback.
“We are pleased to have added the Rett syndrome program to our clinical stage product pipeline that focuses on novel uses and delivery forms of ketamine in the treatment of mental health, neurological and pain disorders,” said Fabio Chianelli, CEO of PharmaTher. “In research, ketamine has shown the potential for treating Rett syndrome. We will work with CWRU and the clinical trial team in pursuing discussions with the FDA to determine all regulatory and clinical options that could expedite the pathway towards having ketamine available for Rett syndrome patients.”
Currently, there is no known cure or FDA-approved drugs for treating Rett syndrome. According to the Rett Syndrome Foundation, Rett syndrome is a rare genetic neurological disorder that occurs almost exclusively in girls. It leads to severe impairments in their ability to speak, walk, eat, and even breathe easily. Prominent features of Rett syndrome include near constant repetitive hand movements and loss of purposeful hand use. Rett syndrome is usually recognized in children between 6 to 18 months. Rett syndrome is caused by mutations on the X chromosome on a gene called MECP2. Rett syndrome occurs worldwide in 1 of every 10,000 female births, and is much rarer in boys.
Ketamine has the potential to treat Rett syndrome, which has been independently validated in two different laboratories in two different strains of Mecp2 mice and has completed a Phase 2 clinical trial with Rett syndrome, with results not published. The therapeutic potential of ketamine for treating Rett syndrome was first demonstrated by Dr. David M. Katz, Professor Emeritus, Department of Neurosciences, School of Medicine at CWRU, and colleagues, who found that treatment of heterozygous female Mecp2 mutant mice with a subanesthetic dose of ketamine (8 mg/kg) acutely reversed abnormalities in Fos expression and sensorimotor function [1]. Chronic administration of ketamine was also found to improve symptoms and extend lifespan in null male Mecp2 mutants [2]. The ability of low-dose ketamine to improve function across a broad range of symptoms may be related to its ability to increase cortical network activity, possibly by selective inhibition of GABAergic interneurons [3], as well as to decrease synaptic excitability in brainstem networks important for respiratory and autonomic control [4]. Thus, ketamine may be ideally suited to redress the imbalance between cortical and brainstem activity that characterizes the MeCP2-deficient brain. Moreover, in addition to its acute effects on circuit function, work in other disease models has shown that ketamine also rapidly stimulates dendritic growth, BDNF levels, and expression of key synaptic proteins [5, 6], at least in part through activation of mTOR signaling, which is deficient in Mecp2 mutants [7]. These findings suggest that, in addition to acute rescue of neurological function, ketamine also has the potential to promote synaptic repair in Rett syndrome by enhancing structural and functional connectivity, as previously shown in animal models of depression and stress [8].
Under the terms of the Agreement, PharmaTher gained an exclusive option for up to 12 months to evaluate the regulatory, clinical development and commercialization plan for CWRU’s intellectual property portfolio, which includes, US issued patent no. 11,213,494 and US provisional patent no. 62/312,749 entitled, “Composition and method for the treatment of pervasive development disorders”, and US provisional patent no. 62/004,695 entitled, “Acute and sustained effects of low-dose ketamine treatment in mouse models of Rett Syndrome.” Consistent with industry standards, PharmaTher paid a one-time fee for entering into the Agreement, and should the Company elect to exercise its option, both the Company and CWRU will negotiate a license agreement.
About PharmaTher Holdings Ltd.
PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is a specialty pharmaceutical company focused on developing and commercializing novel uses and delivery forms of ketamine to treat mental health, neurological and pain disorders. PharmaTher’s product portfolio consists of KETARX™ (ketamine) delivered by intravenous injection, intradermal microneedle patch, and subcutaneous pump administration. Learn more at PharmaTher.com.
For more information about PharmaTher, please contact:
Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com
Hadn’t forgotten but this deal just won’t suffice. More deals needed. Way more.
The tech appears very innovative however, the CEO Bunka should be replaced in my opinion. Pays himself an inflated package but is yet to significantly monetize the business to merit or justify it.
New, more capable CEO preferred to sign deals and create shareholder value.
Bag holders mostly at this point we “Long” investors are.
Excellent. As anticipated. Huge future for SHIB too IMO.